(Reuters) – Bristol-Myers Squibb Co mentioned on Friday the U.S. Meals and Drug Administration permitted its therapy, Opdivo, for sufferers whose lung most cancers had progressed even after present process chemotherapy and at the very least one different remedy. FILE PHOTO: Brand of world biopharmaceutical firm Bristol-Myers Squibb is pictured on the shirt of an worker in Le Passage, close to Agen, France, March 29, 2018. REUTERS/Regis Duvignau/File Photograph The drug competes with Merck & Co’s Keytruda and belongs to a category of therapies that work by activating the immune system to assault tumors. Each therapies have racked up approvals for indications, together with melanoma, lung most cancers and head and neck most cancers. Gross sales of each the medicine are neck and neck, with Opdivo producing $1.63 billion within the second quarter and Keytruda $1.67 billion. Bristol-Myers mentioned Opdivo is the primary immunooncology therapy permitted for sufferers with small cell lung most cancers, which accounts for about 10 to 15 % of all lung cancers. Bristol-Myers shares rose zero.5 % to $61.40 in premarket buying and selling. Reporting by Aakash Jagadeesh Babu and Ashwin Shyam in Bengaluru; Enhancing by Anil D’SilvaOur Requirements:The Thomson Reuters Belief Rules.